Selective KCa3.1 Activators SKA-111 SKA-121
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological activators of KCa2/3 channels lack selectivity for KCa3.1 channels, leading to unintended effects such as sedation and heart rate reduction due to activation of KCa2 channels, which complicates their use as antihypertensives and endothelial-targeted therapies.
Innovation Solution
Development of selective KCa3.1 activators, such as SKA-111 and SKA-121, which exhibit 40-120-fold selectivity over KCa2 channels, achieved through structural modifications of benzothiazole and naphthooxazole scaffolds, allowing for targeted activation of KCa3.1 channels without affecting KCa2 channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective KCa2/3 channel activators are used, then KCa3.1 channels are activated for antihypertensive therapy, but KCa2 channels are also activated causing sedation and heart rate reduction
Solution Approach 1:
The patent applies local quality by developing compounds with differential affinity for specific channel subtypes. The naphthooxazole and benzoxazole compounds are designed to selectively interact with KCa3.1 channels while minimizing interaction with KCa2 channels, achieving localized pharmacological action on the target channel subtype.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structure parameters of the parent compound SKA-31. Specific substitutions at positions 5 and 6 of the naphthooxazole ring system, and modifications of the benzoxazole scaffold, create compounds with altered pharmacological parameters including increased selectivity for KCa3.1 over KCa2 channels.
2Measurement precision
If compound SKA-111 is used, then potent KCa3.1 activation is achieved, but high brain penetration causes loss of selectivity
Solution Approach 1:
The patent applies local quality by creating compounds with different tissue distribution profiles. SKA-121 is specifically designed to have reduced brain penetration compared to SKA-111, creating a local concentration gradient that maintains selectivity in peripheral tissues while avoiding central nervous system effects.
3Object-generated harmful factors
If compound SKA-121 is used, then KCa3.1 selectivity is maintained, but shorter half-life reduces prolonged therapeutic effects
Solution Approach 1:
The patent applies dynamics by creating a profile of compounds with varying half-lives. SKA-121 exhibits shorter half-life with rapid onset and offset, which can be advantageous for certain applications requiring reversible effects, while SKA-111 provides prolonged effects for conditions requiring sustained action. The dynamic properties can be matched to therapeutic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SKA-111 and SKA-121 effectively lower blood pressure without significantly reducing heart rate, demonstrating KCa3.1 selectivity in vivo and in vitro, with SKA-121 maintaining selectivity due to its shorter half-life and reduced brain penetration, while SKA-111 shows prolonged effects but loses selectivity due to high brain penetration.
Implementation Method 1
Selective activators of the intermediate conductance CA2+-activated K+ channel KCa3.1
Data Source
AI summary
Benzoxazole and indole type KCa3.1 activators as well as the therapeutic uses of such compounds in human or animal subjects and their use in ex vivo preservation of organs or tissues.